As part of an ongoing reorganization, Endo Pharmaceuticals will close a manufacturing plant in Huntsville, Ala., and eliminate 875 jobs, which amounts to 19 percent of its global workforce and is only the latest in a string of cutbacks and retrenchments.
By closing the plant, which primarily makes about three dozen different generic drugs, Endo hopes to save between $55 million and $65 million by the end of next year, according to documents filed with the U.S. Securities and Exchange Commission. The company also operates a distribution center there.
About the Author Reprints
